Send to

Choose Destination
Clin Lymphoma Myeloma Leuk. 2011 Jun;11 Suppl 1:S46-8. doi: 10.1016/j.clml.2011.04.003. Epub 2011 May 7.

Allogeneic stem cell transplantation for myelodysplastic syndromes: critical for cure?

Author information

Department of Tumor Immunology, Nijmegen Centre for Life Sciences, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.


Allogeneic stem cell transplantation (SCT) is the treatment of choice for young patients (age ≤ 55 years) with myelodysplastic syndromes (MDS) characterized by poor-risk or intermediate-risk cytogenetics, who have a histocompatible related or unrelated donor. For patients who lack an human leukocyte antigen-compatible donor, autologous SCT, or chemotherapy may be good alternatives for those with MDS and with good-risk cytogenetic characteristics. Iron toxicity is an underestimated cause of hematopoietic stem cell transplantation (HSCT) treatment-related mortality. The pathogenesis, diagnosis, and monitoring of iron-induced organ damage are currently topics of investigation. Prospective studies on the prevention or treatment of iron toxicity before HSCT and/or after HSCT are necessary.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center